December 03, 2014
A California federal judge on Tuesday refused Neurovision Medical Products Inc.'s request for attorneys' fees after NuVasive Inc. was found to have infringed its rival's trademarks and lost a $30 million verdict, ruling the suit didn't meet the "exceptional case" standard under the Lanham Act.
September 24, 2014
A California federal judge on Wednesday canceled trademark registrations held by NuVasive Inc. for the word "neurovision" after the company was found to have infringed its rival Neurovision Medical Products Inc.'s trademarks, and also upheld a $30 million verdict awarded to Neurovision for the alleged infringement.
August 06, 2014
A California federal judge refused Tuesday to throw out a jury's $30 million verdict against medical device company NuVasive Inc. in a trademark infringement suit filed by rival Neurovision Medical Products Inc. over NuVasive’s use of the word "neurovision," finding the verdict wasn’t contrary to the weight of evidence.
August 04, 2014
NuVasive Inc. urged a California federal judge on Monday to throw out a jury's $30 million verdict against it and grant a third trademark infringement trial over its use of the word "neurovision," saying the award was excessive and rival Neurovision Medical Products Inc. improperly described barred evidence to jurors. (Correction: An earlier story misstated the prevailing party in Judge Fischer's tentative ruling. The error has been corrected.)
April 04, 2014
A California federal jury on Thursday found in favor of Neurovision Medical Products Inc. in its second trial over claims that NuVasive Inc. infringed its rival's trademark, saying NuVasive owes $30 million following the Ninth Circuit's reversal of a $60 million verdict against NuVasive.
April 01, 2014
A NuVasive Inc. executive defended the medical device company before a California federal jury Tuesday in the second trial over claims that NuVasive infringed rival Neurovision Medical Products Inc.'s trademark, following the Ninth Circuit's reversal of a $60 million verdict against NuVasive.